A Phase 3 interventional study of CinnaPoietin® and Eprex® in Anemia in End-Stage Renal Disease, sponsored by Cinnagen. Completed at 8 sites in Iran, Islamic Republic of. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-12-18.
Sponsored by Cinnagen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Kidney Failure, Chronic with a site in Iran, Islamic Republic of — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Iran, Islamic Republic of.
Among the 13 studies in Kidney Failure, Chronic with a site in Iran, Islamic Republic of, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is the only one in phase 3, and was the 8th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 13 studies in Kidney Failure, Chronic with a site in Iran, Islamic Republic of is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 3 · Phase 4 2
First in 2008; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 77 across the 10 interventional studies, 120 across the 3 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 6 most frequent:
Cinnagen is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
Cinnagen has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Kidney Failure, Chronic with a site in Iran, Islamic Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase III, randomized, two-armed, parallel, double-blind, active-controlled clinical trial is designed to compare efficacy and safety of CinnaPoietin® (Beta erythropoietin) and Eprex® (epoetin alpha) on the treatment of anemia in 156 End-Stage Renal Disease hemodialysis patients. 156 patients have been planned to randomize and assign to receive CinnaPoietin® or Eprex® for a 26-week period. Administration dose for patients who are treated with erythropoietin is the similar dose of the previously administered amount (IV or SC without any change). After then, dose adjustment will be made based on patients' response. The primary objective of this study is to compare the efficacy of CinnaPoietin® with Eprex®. The secondary objectives of this study are further comparison and evaluation of efficacy along with safety between CinnaPoietin® and Eprex®.
This study is a phase III, randomized, two-armed, parallel, double-blind (patient and assessor blinded), active-controlled noninferiority clinical trial to determine the non-inferior therapeutic efficacy and safety between CinnaPoietin® (Beta erythropoietin) and Eprex® (epoetin alpha) on the treatment of anemia in ESRD patient under hemodialysis. After signing the written informed consents, 156 patients have been planned to randomize and assign to receive CinnaPoietin® or Eprex® for a 26-weeks period. Administration dose for patients who are treated with erythropoietin is the similar dose of the previously administered amount (IV or SC without any change). After then, dose adjustment will be made based on patients' response. In addition to main intervention, Nephrovit tablet/day and B12 100 mcg/month were prescribed for patients. The primary objective of this study is to compare the efficacy of CinnaPoietin® with Eprex®. The secondary objectives of this study are further comparison and evaluation of efficacy and safety.
The clinical trial will be conducted according to the GCP considerations. A comprehensive validation check program is used to verify the data, and discrepancy reports are generated accordingly for resolution by the investigator.
In order to ensure the use of standard and unified procedure of each test, monitoring of each site and laboratory site are going to be applied by sponsor monitoring team and CRO as external monitoring team.
The same prefilled syringe is used for CinnaPoietin® to be sure that there is no difference between CinnaPoietin® and Eprex® as brand drug. The drugs will be relabeled, and the same label is used for both prefilled syringe. So neither investigators nor subjects are able to notice any differences between them and are blind to the assignment.
Determination of sample size 156 patients will be equally (1:1) divided into intervention arms (78 in each group considering drop out) for achieving 80% power in order to determine non-inferiority using a one-sided, independent sample t-test. The margin of non-inferiority is -1.00.
The true difference between the means is assumed to be -0.500. The significance level (alpha) of the test is 0.05. The data are drawn from populations with standard deviations of 1.200 and 1.200.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
Drug: CinnaPoietin® · Drug: Nephrovit · Drug: Vitamin B12 Injection
The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
Drug: Eprex® · Drug: Nephrovit · Drug: Vitamin B12 Injection
The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Also known as: Beta erythropoietin
The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Also known as: Epoetin alpha
Nephrovit tablet is daily administered to all the patients.
Vitamin B12 is monthly injected to all the patients.
Mean Hb Change Level During the Last Four Weeks of Treatment
The primary endpoints of this study is to assess mean Hb change level during the last four weeks of treatment.
Time frame: Week 22 to week 26
Mean Weekly Epoetin Dosage Per kg Body Weight During the Last Four Weeks of Treatment
The mean weekly epoetin dosage per kg body weight during the last four weeks of treatment necessary to maintain the Hb level within 10-12 g/dl during the last four weeks of treatment is considered as the second primary endpoint.
Time frame: Week 22 to week 26
The Proportion of Patients With Any Permanent or Transient Dose Change
The proportion of patients with any permanent or transient dose change during 26 weeks.
Time frame: 26 weeks
The Proportion of Patients With Any Hb Measurement Outside the Target Range (10-12 g/dl)
The proportion of patients with any Hb measurement outside the target range (10-12 g/dl) during 26 weeks.
Time frame: 26 weeks
The Proportion of Patients Needed Blood Transfusions
The proportion of patients needed blood transfusions during 26 weeks.
Time frame: 26 weeks
The Proportion of Patients With Treatment Success
Treatment success is considered as Hb concentration equal to or more than 11.0 g/dl and two consecutive weeks without any blood transfusion within the preceding three months
Time frame: Week 12 to week 26
The Proportion of Patients With Maintenance Success
Maintenance success is considered as maintenance success is considered as maintenance of mean Hb concentration of 11.0 ± 1.0 g/dl for at least four consecutive weeks
Time frame: 26 weeks
The Percentage of Patients With Hb Measurements More Than 10.0 g/dl
The percentage of patients with Hb measurements more than 10.0 g/dl from week 22 to week 26.
Time frame: Week 22 to week 26
The Percentage of Patients With Hematocrit Measurements More Than 30%
The percentage of patients with hematocrit measurements more than 30% from week 22 to week 26.
Time frame: Week 22 to week 26
The Incidence of Hb Levels Above 13 g/dl
The first safety endpoint is the proportion of patients with at least one Hb measurement above 13 g/dL.
Time frame: 26 weeks
The Proportion of Patients With an Increase in Hb Concentration of > 1.0 g/dl for Four Consecutive Weeks
The proportion of patients with an increase in Hb concentration of \> 1.0 g/dl for four consecutive weeks during 26 weeks.
Time frame: 26 weeks
The Incidence of Adverse Events
The incidence of adverse events during 26 weeks.
Time frame: 26 weeks
| Milestone | CinnaPoietin® | Eprex® |
|---|---|---|
| Started | 78 | 78 |
| Completed | 67 | 56 |
| Not completed | 11 | 22 |
| Withdrew: Death | 5 | 5 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Withdrawal by subject | 2 | 7 |
| Withdrew: Physician decision | 3 | 6 |
The primary endpoints of this study is to assess mean Hb change level during the last four weeks of treatment.
| g/dL | CinnaPoietin® | Eprex® |
|---|---|---|
| Mean Hb Change Level During the Last Four Weeks of Treatment | 0.4 ± 1.26 | 0.74 ± 1.39 |
The mean weekly epoetin dosage per kg body weight during the last four weeks of treatment necessary to maintain the Hb level within 10-12 g/dl during the last four weeks of treatment is considered as the second primary endpoint.
| IU/Kg/week | CinnaPoietin® | Eprex® |
|---|---|---|
| Mean Weekly Epoetin Dosage Per kg Body Weight During the Last Four Weeks of Treatment | 117.02 ± 54.5 | 110.01 ± 49.27 |
The proportion of patients with any permanent or transient dose change during 26 weeks.
| proportion of patients | CinnaPoietin® | Eprex® |
|---|---|---|
| The Proportion of Patients With Any Permanent or Transient Dose Change | 0.9 | 0.95 |
The proportion of patients with any Hb measurement outside the target range (10-12 g/dl) during 26 weeks.
| proportion of patients | CinnaPoietin® | Eprex® |
|---|---|---|
| The Proportion of Patients With Any Hb Measurement Outside the Target Range (10-12 g/dl) | 0.92 | 1 |
The proportion of patients needed blood transfusions during 26 weeks.
| proportion of patients | CinnaPoietin® | Eprex® |
|---|---|---|
| The Proportion of Patients Needed Blood Transfusions | 0.04 | 0.04 |
Treatment success is considered as Hb concentration equal to or more than 11.0 g/dl and two consecutive weeks without any blood transfusion within the preceding three months
| proportion of patients | CinnaPoietin® | Eprex® |
|---|---|---|
| The Proportion of Patients With Treatment Success | 0.41 | 0.44 |
Maintenance success is considered as maintenance success is considered as maintenance of mean Hb concentration of 11.0 ± 1.0 g/dl for at least four consecutive weeks
| proportion of patients | CinnaPoietin® | Eprex® |
|---|---|---|
| The Proportion of Patients With Maintenance Success | 0.71 | 0.43 |
The percentage of patients with Hb measurements more than 10.0 g/dl from week 22 to week 26.
| Participants | CinnaPoietin® | Eprex® |
|---|---|---|
| The Percentage of Patients With Hb Measurements More Than 10.0 g/dl | 55 | 48 |
The percentage of patients with hematocrit measurements more than 30% from week 22 to week 26.
| percentage of patients | CinnaPoietin® | Eprex® |
|---|---|---|
| The Percentage of Patients With Hematocrit Measurements More Than 30% | 86.76 | 92.86 |
The first safety endpoint is the proportion of patients with at least one Hb measurement above 13 g/dL.
| Participants | CinnaPoietin® | Eprex® |
|---|---|---|
| The Incidence of Hb Levels Above 13 g/dl | 31 | 42 |
The proportion of patients with an increase in Hb concentration of \> 1.0 g/dl for four consecutive weeks during 26 weeks.
| Participants | CinnaPoietin® | Eprex® |
|---|---|---|
| The Proportion of Patients With an Increase in Hb Concentration of > 1.0 g/dl for Four Consecutive Weeks | 44 | 41 |
The incidence of adverse events during 26 weeks.
| Participants | CinnaPoietin® | Eprex® |
|---|---|---|
| The Incidence of Adverse Events | 23 | 18 |
Collected over 26 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CinnaPoietin® | 5/78 (6.4%) | 14/78 (17.9%) | 11/78 (14.1%) |
| Eprex® | 5/78 (6.4%) | 7/78 (9%) | 12/78 (15.4%) |
| Event | CinnaPoietin® | Eprex® |
|---|---|---|
| (Skin reaction, Catheter defect, Disability catheter, Filter clots, pain in injection site, skin reaGeneral disorders | 4/78 | 0/78 |
| Palpitation, Cardiac Function Impairment, Cardiac Infraction, Chest Pain, Tachycardia)Cardiac disorders | 2/78 | 3/78 |
| (Pneumonia, Infection of right hand Lower than the fistula)Infections and infestations | 2/78 | 0/78 |
| (CO toxicity, transplantation complication)Injury, poisoning and procedural complications | 0/78 | 2/78 |
| (tearing of tendon in both knees, back pain, Musculoskeletal-Bone pain, knee tenderness due to jointMusculoskeletal and connective tissue disorders | 2/78 | 1/78 |
| Inflation on AnkleRenal and urinary disorders | 1/78 | 0/78 |
| GallstonesHepatobiliary disorders | 1/78 | 0/78 |
| (Respiratory disorder, chest pain and dyspenea, dyspnea)Respiratory, thoracic and mediastinal disorders | 1/78 | 0/78 |
| echymosis due to recent car accident, itching)Skin and subcutaneous tissue disorders | 0/78 | 1/78 |
| Cardiac pacemaker AND Valve Replacement, orthopedic surgery)Surgical and medical procedures | 1/78 | 0/78 |
| Event | CinnaPoietin® | Eprex® |
|---|---|---|
| (Palpitation, Cardiac Function Impairment, Cardiac Infraction, Chest Pain, Tachycardia)Cardiac disorders | 1/78 | 3/78 |
| (Skin reaction, Catheter defect, Disability catheter, Filter clots, pain in injection site, skin reaGeneral disorders | 3/78 | 1/78 |
| (Respiratory disorder, chest pain and dyspenea, dyspnea)Respiratory, thoracic and mediastinal disorders | 2/78 | 0/78 |
| (itching, echymosis due to recent car accident, itching)Skin and subcutaneous tissue disorders | 0/78 | 2/78 |
| (blood clotting, Bleeding catheter, Hemorrage, Vascular disorders)Vascular disorders | 2/78 | 0/78 |
| (Eosinophilia, Thrombocytopenia)Blood and lymphatic system disorders | 0/78 | 1/78 |
| (Pneumonia, Infection of right hand Lower than the fistula)Infections and infestations | 1/78 | 0/78 |
| HyperkalemiaMetabolism and nutrition disorders | 0/78 | 1/78 |
| (tearing of tendon in both knees, back pain, Musculoskeletal-Bone pain, knee tenderness due to jointMusculoskeletal and connective tissue disorders | 0/78 | 1/78 |
| (numbness in the wrist, dizziness)Nervous system disorders | 1/78 | 1/78 |
| Age, Categorical(Participants) | CinnaPoietin® | Eprex® | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 60 | 69 | 129 |
| >=65 years | 18 | 9 | 27 |
| Age, Continuous(years) | CinnaPoietin® | Eprex® | Total |
|---|---|---|---|
| Mean | 55.02 ± 11.38 | 50.01 ± 12.72 | 52.53 ± 12.28 |
| Sex: Female, Male(Participants) | CinnaPoietin® | Eprex® | Total |
|---|---|---|---|
| Female | 33 | 33 | 66 |
| Male | 45 | 45 | 90 |
| Race (NIH/OMB)(Participants) | CinnaPoietin® | Eprex® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 78 | 78 | 156 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | CinnaPoietin® | Eprex® | Total |
|---|---|---|---|
| Iran | 78 | 78 | 156 |
| Hemoglobin concentration(g/dL) | CinnaPoietin® | Eprex® | Total |
|---|---|---|---|
| Mean | 10.41 ± 0.89 | 10.64 ± 0.82 | 10.53 ± 0.86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2016 to primary completion in Jul 2017, 12 months.
Results were first posted in Nov 2019, 2 years 3 months after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 12 months is below that.
Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cinnagen